Comparative Pharmacology
Head-to-head clinical analysis: QINLOCK versus ROZLYTREK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QINLOCK versus ROZLYTREK.
QINLOCK vs ROZLYTREK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ripretinib is a switch-control tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) kinase signaling. It binds to both the switch pocket and the activation loop of KIT and PDGFRA, preventing kinase activation and inhibiting downstream signaling pathways involved in tumor cell proliferation and survival.
Entrectinib is a potent inhibitor of tropomyosin receptor tyrosine kinases (TRK) A, B, and C, and also inhibits ROS1 and ALK. It blocks downstream signaling pathways including MAPK, PI3K/AKT, and PLCγ, leading to apoptosis and reduced tumor growth in cancers with NTRK or ROS1 fusions.
150 mg orally once daily with food, until disease progression or unacceptable toxicity.
200 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours (range 11–20 hours) in patients with advanced GIST. This supports twice-daily dosing.
Terminal half-life approximately 24 hours; supports once-daily dosing, steady-state reached in ~5 days.
Primarily hepatic metabolism, with <1% excreted unchanged in urine. Fecal excretion accounts for approximately 80% of the administered dose, with renal excretion of unchanged drug being minimal (<1%).
Primarily hepatic metabolism via CYP3A4; 63% of dose recovered in feces (mostly as metabolites), 18% in urine (9% unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor